Abstract
The present systematic review summarizes current evidence regarding the mechanisms of action, the efficacy, and the adverse effects of tyrosine kinase inhibitors (TKIs) in ovarian cancer patients. Phase II and III clinical trials were sought in the PubMed database and in the Clinical Trials.gov registry through September 30, 2015. Seventy-five clinical trials regarding TKIs targeting mainly vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, and sarcoma tyrosine kinase (Src) were yielded. The most promising results were noted with cediranib, nintedanib, and pazopanib. However, drawing universal conclusions about the potential integration of TKIs in ovarian cancer therapy remains elusive. Furthermore, emerging challenges and directions for the future research are critically discussed.
Keywords:
Ovarian cancer; clinical trials; growth factors and receptor; signal transduction.
Publication types
-
Meta-Analysis
-
Review
-
Systematic Review
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials as Topic
-
ErbB Receptors / antagonists & inhibitors
-
Female
-
Humans
-
Molecular Targeted Therapy
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / pathology
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Treatment Outcome
-
src-Family Kinases / antagonists & inhibitors
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
ErbB Receptors
-
Receptors, Platelet-Derived Growth Factor
-
Receptors, Vascular Endothelial Growth Factor
-
src-Family Kinases